Fraud alert: Warning against fraudulent internet recruitment activities. Read more.
We were created out of the courage to think about the future
Everything we do is supported by our value system
Led by the industry veterans and innovative scientists
Three international centres in Poland & the Netherlands
We have brought over 50 scientists back to Poland
Biosimilars are copies of existing biotherapeutics, improving patient access and reducing healthcare costs
We can take biosimilars from concept to commercial supply utilising state-of-the-art facilities
We have a broad pipeline of biosimilars covering multiple therapeutic areas
Our range of manufacturing biosimilar cell lines ready for development and out-licensing
We collaborate and partner with the world’s largest biotechnology companies
Search our open vacancies
Learn why our employees love working here
If you live abroad learn about our beautiful country
We aren’t all scientists, discover what our teams do
Get to know what being part of our team is like
All our latest developments
Presentations, exhibitions, partnering, attendance
Publications, article, brochures and fact sheets
Webinars, explainer videos, corporate films
Interesting articles on the latest developments in biologics
Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”) j...
Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (...
Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”), jointly announ...
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...
European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for biosimilar...
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent...
Zug, Switzerland – MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland, the P...
Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application...
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee...
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has...
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "we...
The place to find all the most innovative research and information on novel biologics and biosimilars.
We have an extensive catalogue of videos introducing our sites, solutions, portfolio and employment opportunities.
You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.
We attend all the major biologics conferences globally as invited speakers, exhibitors and sponsors, find out where we will be below.
Find out about all the latest developments of our portfolio and our partners products and other news from Polpharma Biologics.
Get in touch for more information.
PL
EN
